SecBot SecBot

SLS drug pipeline

$19.15
+156.4% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 REGAL trial succeeds, the earliest potential regulatory submission (BLA) would follow the topline readout in Q4 2026, with an FDA review timeline of roughly 10-12 months thereafter, putting a potential approval in late 2027 or early 2028 at the earliest.

galinpepimut-S Updated Oct 28

What to watch

Watch for the topline Phase 3 REGAL overall survival readout, expected within the next two months (Q4 2026). A positive result showing statistically significant survival benefit could drive the stock toward analyst targets of $30-$35, while a miss or marginal result would likely devastate the stock given the company's pre-revenue status and dependence on this single asset. The ongoing securities investigation adds a secondary legal risk to monitor.

Bull case
  • The REGAL trial passed its pre-specified futility analysis in January 2025, suggesting the Data Monitoring Committee saw enough efficacy signal to continue (source: cancernetwork.com)
  • The trial took longer than originally expected to reach 80 events, which could indicate patients on galinpepimut-S are living longer than the statistical assumptions predicted (source: intobiotech.com)
  • Major institutional investors accumulated heavily in Q2 2026: BlackRock held $222M, State Street added 55% to reach $192M, and Vanguard added 48% to reach $121M
Bear case
  • STAT News biotech columnist Adam Feuerstein predicted the REGAL trial will fail, stating galinpepimut-S is not expected to show a survival benefit over standard of care (source: statnews.com)
  • The trial was delayed by nearly a year to reach 80 events, raising significant doubts about the magnitude of any potential efficacy signal (source: statnews.com)
  • Pomerantz LLP and other law firms have launched securities fraud investigations into whether SELLAS delayed disclosing that the 80th event had been reached, causing a 13% stock drop on August 28, 2026 (source: pomlaw.com)
◆ mixed
Impact
PhasePhase 2
Time to marketSLS009 is in Phase 2 testing and has not yet entered a pivotal/registrational trial. If the first-line AML data is positive and the FDA agrees on a registration pathway, a potential NDA filing is likely several years away. The drug could also benefit from Fast Track designation, which enables rolling review and priority review if criteria are met.

SLS009 tambiciclib Updated Oct 28

What to watch

The next hard catalyst for SLS009 is the Phase 2 first-line AML topline data readout expected in Q4 2026 (within approximately 2 months). Positive results could validate SLS009's potential as a backbone AML therapy and significantly boost SLS shares, while negative or mixed data would weigh on the stock. Note that the company's Phase 3 REGAL trial for GPS also just reached its 80th event today, creating a dense catalyst cluster for SLS in the near term.

Bull case
  • Phase 2 r/r AML trial met all primary endpoints with a 44-46% ORR and median overall survival of 8.9 months (vs. ~2.4 months historical benchmark), demonstrating strong proof of concept in a difficult-to-treat population.
  • FDA granted Fast Track, Orphan Drug, and two Rare Pediatric Disease Designations for SLS009, signaling regulatory interest and potential Priority Review Voucher eligibility upon approval.
  • The company held $138.3M in cash as of June 30, 2026, providing a multi-year runway to fund both SLS009 and the GPS Phase 3 REGAL program without near-term dilution risk.
Bear case
  • CDK9 inhibitors remain an unproven drug class with no FDA-approved agents; clinical or regulatory setbacks for any CDK9 program could dent confidence in SLS009.
  • The ongoing first-line AML Phase 2 trial (80 patients) is still enrolling (28 of 80 as of Q2 2026) and the drug has not yet entered a pivotal registration trial, meaning commercial approval is years away at best.
  • SELLAS has two value-driving programs (GPS Phase 3 and SLS009 Phase 2) and no approved products or revenue; either program's failure would heavily pressure the single-product-company-style valuation.